Navigation Links
Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals

LA JOLLA, Calif., April 14 /PRNewswire/ -- Zenobia Therapeutics, Inc., the leader in fragment-based lead discovery for diseases of the central nervous system, announced successful completion of the first phase of its services agreement with Syntonix Pharmaceuticals, a wholly-owned subsidiary of Biogen Idec (Nasdaq: BIIB). As part of the agreement, Syntonix gains access to Zenobia's technology and expertise in structural biology, crystallization and X-ray structure determination. Zenobia completed three unique protein structures during the first five months of the agreement. The agreement includes research funding and milestone payments.

"Syntonix challenged us with a difficult program, and through close collaboration between our scientists, we are pleased to deliver results," said Vicki Nienaber, Ph.D., President, CSO and founder of Zenobia.

The program required dedicated expertise in protein crystallization including specialized techniques and multiple rounds of optimization.

"It was a challenging target to crystallize, with more than 800 conditions being screened followed by careful optimization of multiple parameters, which was a key for successful structure determination," said Vandana Sridhar, head of Zenobia's crystallization group.

Zenobia has rapid access to high-energy synchrotron sources for data collection through an agreement with Shamrock Biostructures, located near the Advanced Photon Source (APS) in Chicago, IL.

"Synchrotron radiation was required for this program, and we are fortunate to have routine access to the only third-generation synchrotron in the U.S. through our agreement with Shamrock," said Dr. Nienaber.

"Having access to these new experimental crystal structures will allow us to more efficiently design and develop our internal drug candidates," said Adam Mezo, Ph.D., Director of Chemistry at Syntonix.

About Zenobia

Zenobia provides a commercial fragment library and access to their structural biology, crystallography and fragment-based lead discovery expertise through partnerships, consulting and collaborations. Zenobia's internal programs combine fragment-based lead discovery with the expertise of biologists and clinicians to find treatments for devastating illnesses for which there are no disease-altering treatments such as Parkinson's and Huntington's diseases.

SOURCE Zenobia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
3. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $15 Million of Preferred Stock
4. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
5. Oxygen Biotherapeutics, Inc. CEO Posts New Blog Entry
6. Cell Therapeutics Satisfies NASDAQ Listing Requirements to Continue to Trade on NASDAQ Capital Market
7. TorreyPines Therapeutics Receives Notice of Non-Compliance with Nasdaq Continued Listing Requirements
8. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
9. Arno Therapeutics Reports 2008 Year-End Financial Results
10. Stockholder Suits Related to TorreyPines Therapeutics, Inc. Dismissed
11. Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland
Post Your Comments:
(Date:10/13/2015)... 2015      Q BioMed Inc ... entered into a strategic relationship with Wombat Capital, Ltd., ... Paris, France based strategic and scientific ... This collaborative arrangement gives Q BioMed and its ... as well as long established pharmaceutical industry relationships. The ...
(Date:10/13/2015)... Farmington Hills, MI (PRWEB) , ... October 13, ... ... leading Michigan-based manufacturer and distributor of automation systems, material handling solutions and components, ... , Located off I-94 near State Street, the facility is Exotic’s second major ...
(Date:10/13/2015)... ... October 13, 2015 , ... The ... school age children in the areas of Science, Technology, Engineering and Mathematics. The ... national economy, and the program aims to increase the number of students who ...
(Date:10/12/2015)... , Oct.12, 2015  MiMedx Group, Inc. (NASDAQ: ... amniotic tissue and patent-protected processes to develop and market ... Orthopedic, Spine, Sports Medicine, Ophthalmic, and the Dental sectors ... had been filed against the Company has been dismissed ... , Chairman and CEO, stated, "As we suspected, this ...
Breaking Biology Technology:
(Date:10/9/2015)... Oct. 09 2015 ... of the "Samsung Galaxy S6 Fingerprint ... to their offering. --> ... "Samsung Galaxy S6 Fingerprint Sensor - ... offering. --> Research and Markets ...
(Date:10/7/2015)... --> --> According to ... quarter 2015 amounted to around 960 MSEK. This exceeds the ... communicated 20 August 2015. --> ... continued growing demand for the company,s products, the revenues for ... during the third quarter. The revenue guidance for 2015 is ...
(Date:10/5/2015)... , October 5, 2015 ... update for NXT-ID, Inc. (NASDAQ: NXTD ), a ... market. --> ) releases ... (NASDAQ: NXTD ), a biometric authentication company focused ... SoundView Technology Group ( ) releases ...
Breaking Biology News(10 mins):